ismagilov Clinical-stage biopharmaceutical company Alumis ( NASDAQ: ALMS ) is having a rough day on its first day of trading with shares trading well below its IPO price of $16/share. As of 130p ET, shares were trading at $12.50, an almost 22% decline from its IPO price.
Although the IPO was priced at $16, when the stock began trading shortly after 1230p, it opened at $13.48. More on Alumis Inc.
Alumis' $100 Million IPO: Promising Psoriasis Treatment Results Alumis prices IPO at $16 per share Immunology drug developer Alumis files for $100M IPO Financial information for Alumis Inc..